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Ciliary neurotrophic factor (CNTF) is a potent protective factor
for striatal neurons in animal models of Huntington’s disease
(HD). Clinical application of this potential therapeutic still re-
quires the design and optimization of delivery systems. In the
case of HD, spatial spread in the vast volume occupied by the
striatum and long-term delivery of the factor are particular
challenges for these systems. We explored the potential of
adenovirus-mediated gene transfer to fulfill these requirements
by studying the functional and anatomical effects of single-site
striatal delivery of CNTF recombinant vectors in a rat model of
HD. In an initial series of experiments, unilateral injections of
CNTF adenovirus were performed in rats 10, 30, or 90 d before
a 5 d neurotoxic treatment with systemic 3-nitropropionic acid
(3NP). Preservation of striatal neurons was observed at all time
points, demonstrating temporally extended neuroprotective ef-
fects of the CNTF adenovirus. In a second series of experi-
ments, bilateral injections of CNTF adenovirus were performed
in the medial aspect of the striatum 10 d before starting 3NP
intoxication. Despite placement of the CNTF-producing vector
outside the lateral striatal area susceptible to lesion, massive
protection of corticostriatopallidal circuits was observed, asso-
ciated with significant behavioral benefits. This spatial spread
of neuroprotection is discussed with reference to the retrograde
transport of the adenovirus vector and the anterograde trans-
port of the transgenic CNTF. Overall, adenovirus-mediated
CNTF gene transfer appears to be a potentially useful delivery
system for widespread, long-term circuit neuroprotection in HD
patients.
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Protection of GABAergic striatal neurons by ciliary neurotrophic
factor (CNTF) is a promising prospect for slowing down the
pathologic process of Huntington’s disease (HD). A number of
studies have indeed demonstrated that intracerebral administra-
tion of CNTF using either minipumps (Anderson et al., 1996) or
encapsulated genetically engineered cells (Emerich et al., 1996;
Mittoux et al., 2000) significantly decreases the extent of striatal
cell loss produced by a variety of neurotoxins in rats or nonhuman
primates. In vitro experiments have also confirmed a protective
effect of CNTF on cells genetically engineered to express the
mutated form of the huntingtin protein (Saudou et al., 1998).
Finding an efficient way to deliver CNTF to striatal neurons in
patients remains unresolved. Systemic administration of CNTF is
not appropriate, because it practically does not cross the blood–
brain barrier and induces major side effects and likely, an immune
reaction. Therefore direct intracerebral delivery using in vivo
gene therapy constitutes an interesting alternative approach. Ad-
enoviruses are among the most efficient vectors to transfer genes
into the brain (Akli et al., 1993; Bajocchi et al., 1993; Davidson et
al., 1993; Le Gal La Salle et al., 1993), but their clinical relevance
has often been questioned, primarily because of three potential
drawbacks: toxicity (Akli et al., 1993; Caillaud et al., 1993; Byrnes
et al., 1995), lack of spatial dispersion after intraparenchymal
administration (Lisovoski et al., 1997; Peltekian et al., 1997), and
suspected decrease in gene expression over time.
Regarding cytotoxicity, a concurrent decrease in toxicity and
increase in transgene expression has been obtained recently using
a low (108 pfu) titer of vector (Bohn et al., 1999). With regard
to the second point, the lack of dispersion of the adenoviral
particles at the injection site may be partly compensated for by
intrinsic properties of adenoviral vectors such as retrograde trans-
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port of the transgene to the cell bodies and anterograde transport
of the transgene product to nerve terminals including axonal
collaterals (Akli et al., 1993; Kuo et al., 1995; Lisovoski et al.,
1997; Terashima et al., 1997). Interestingly, such spreading of the
transgene has been shown previously to trigger astrocyte differ-
entiation in regions located in the projection zones of retro-
gradely transduced neurons, after intrastriatal injection of CNTF
recombinant adenovirus vectors (Lisovoski et al., 1997).
In this context, we aimed to further explore the neuroprotec-
tive potential of a CNTF recombinant adenovirus vector in a rat
model of striatal neurodegeneration (Ouary et al., 2000). In this
model, as in HD, the cell loss is primarily observed in the
striatum, but at later times it also extends to other cerebral areas
anatomically connected to the caudate–putamen complex, such as
various upstream cortical areas and the downstream globus pal-
lidus. The present work investigated whether the use of a single-
site striatal administration of low-titer CNTF adenoviral vector
would confer widespread and long-lasting corticostriatopallidal
neuroprotection in a chronic lesion rat model of HD.
MATERIALS AND METHODS
Experimental design. Two separate experiments were performed to ex-
amine, respectively, the temporal and the spatial extent of the neuropro-
tective effects of a single intrastriatal administration of 5  10 8 pfu of a
CNTF recombinant adenovirus vector.
In the first set of experiments, we studied the time course of the
neuroprotective effect of CNTF. Adult Lewis rats were unilaterally
infected in one striatum with either a CNTF (AdRSV.CNTF) or a
control LacZ (AdRSV.LacZ) recombinant adenovirus vector. The sur-
vival of striatal neurons was challenged either 10, 30, or 90 d later by
systemically administering 3-nitropropionic acid (3NP), as described
previously (Ouary et al., 2000). Animals were killed at the end of 5 d of
neurotoxic treatment for histological assessment and quantification of
striatal lesion volumes. In the second set of experiments, we quantified
the spatial extent of neuroprotection and the behavioral benefits pro-
duced by a single-site, bilateral administration of the CNTF vector into
the medial striatum of adult Lewis rats, challenged 10 d later by systemic
3NP. At the end of the 3NP treatment, the animals were allowed to
recover for 16 d. They were then tested for locomotion activity before
killing and stereological neuronal quantification.
3NP intoxication. A stock solution of 3NP (Fluka, Saint Quentin
Fallavier, France) was made fresh at a concentration of 307–316 mg/ml
in deionized water and adjusted to a pH of 7.4 with 1 M NaOH solution,
keeping the solution below 25°C. The concentration of the stock
solution was calculated according to the weight of the heaviest rat per
group. Osmotic minipumps (2ML4 model; Alzet Corporation, Palo Alto,
CA) were loaded to deliver 60 l per 24 hr for 5 d. The 3NP con-
centration in the pump was adjusted to the exact weight of each animal
at the day of implantation, so that each rat received a dose of 38
mg  kg1  d1. The pumps were implanted subcutaneously in the back
under ketamine–xylazine anesthesia. This intoxication regimen pro-
duces consistent, bilateral striatal degeneration in Lewis rats (Ouary et
al., 2000).
Adenovirus vectors. The adenovirus vectors recombinant for genes
encoding either the rat CNTF gene and an attached sequence encoding
mouse NGF signal peptide to ensure secretion (AdRSV.CNTF) or the
reporter gene -galactosidase (AdRSV.LacZ), under the control of the
long-terminal repeat promoter of the Rous sarcoma virus, have been
described previously (Lisovoski et al., 1997). Both adenovirus vectors
were obtained at titers up to 10 12 pfu/ml.
The AdRSV.CNTF vector has previously demonstrated its biological
activity in vitro and in vivo (Lisovoski et al., 1997; Haase et al., 1999). To
assess the stability and long-term transgene expression of this vector,
mRNA from the striatum of two AdRSV.CNTF-injected rats was isolated
at 3 months after infection by the Trizol method (Invitrogen, Cergy,
France) and a PCR was performed with cDNA derived from 2 g of
RNA, 2.5 U of AmpliTaq Polymerase, and a reaction kit (Superscript
preamplification system; Invitrogen), in a final volume of 50 l. Each
cycle of PCR included 30 sec of denaturation at 95°C, 30 sec of primer
annealing at 55°C, and 1 min of extension/synthesis at 72°C. One cycle of
72°C for 10 min was performed at the end of the 35 cycles. Primers
corresponded to pre-NGF (5-AGCTCACCTCAGTGTCTGGG) and
CNTF exon 2 (5-ACCATCCACTGAGTCAAGGC), therefore exclud-
ing endogenous CNTF mRNA from the analysis (Haase et al., 1999).
Each primer was added at 0.2 M per reaction.
As an additional control for a potential neuroprotective effect by the
inflammatory response triggered by adenovirus vectors, we evaluated the
long-term effects (50 d after infection) of the noncytotoxic titer of LacZ
recombinant vector. We also examined the effects of a 10-fold higher titer
of the same vector, in the same volume. Such a nonspecific neuroprotec-
tive effect was definitively ruled out because there were no statistical
differences in the size of striatal lesions between the infected and
noninfected striatum of rats receiving an intrastriatal injection of either
PBS (n  9), 5  10 8 pfu AdRSV.LacZ (n  8), or 5  10 9 pfu
AdRSV.LacZ (n  6), or between striatal lesions in the each of the three
experimental groups.
Surgery. Male adult Lewis rats (IFFA Credo, Saint-Germain sur
L’Arbresle, France), 12 weeks of age and weighing 300–350 gm (at time
of infection), were used in these studies. The animals were housed in
groups of three to four in a temperature- and humidity-controlled room
that was maintained on a 12 hr light /dark cycle. Food and water were
available ad libitum throughout the experiment. Experimentation was
performed in strict accordance with the recommendations of the Euro-
pean Ethical Committee (EEC) (86/609 EEC), and French National
Ethical Committee (87/848) for care and use of laboratory animals.
Immediately before surgery, rats were anesthetized with a mixture of
ketamine–xylazine (mixture of 15 mg/kg and 3 mg/kg, respectively) and
positioned in a Kopf stereotaxic instrument (David Kopf Instruments,
Les Ulis, France). A midline incision was made in the scalp, and holes
were drilled for the placement of a 5 l Hamilton syringe equipped with
a 28 gauge needle. Rats received a unilateral (n  5–10 in each group;
experiment 1) or bilateral (n  8–9 in each group; experiment 2) striatal
injection of 5  10 8 pfu (adjusted to a final volume of 1 l of PBS) of
either of the two vectors. The stereotaxic coordinates for striatal infec-
tion were: 0.5 mm anterior to Bregma, 3 mm lateral from the sagittal
suture, and 4.5 mm below the dura. These coordinates were selected to
reach the medial third of the striatum (Paxinos and Watson, 1986), so
that the infected/transgene-expressing cells would be located outside the
dorsolateral striatal area that exhibits the maximal neuronal loss after
3NP treatment (Ouary et al., 2000). After infection, the skin was sutured
closed and the animals were allowed to recover in their home cage. At 10,
30, or 90 d after unilateral infection (experiment 1) or 10 d after bilateral
infection (experiment 2), all animals were reanesthetized for implanta-
tion of the 3NP-releasing minipumps.
Control animals (experiment 1) received one unilateral intrastriatal
injection of 1 l of PBS (n  6) and AdRSV.LacZ at a concentration of
5  10 8 (n  8) 10 d before implantation of the 3NP-releasing
minipumps. For experiment 2, 10 animals were implanted with empty
osmotic minipumps and used as sham-operated controls for the behav-
ioral and stereological cell count analyses.
Motor index (experiment 2). Starting on day 1 of the 3NP intoxication
until day 13, animals were evaluated daily for motor impairment. Ani-
mals were rated for the presence or absence of a variety of motor
abnormalities using a rating scale previously designed in our laboratory
(Ouary et al., 2000). As shown in Table 1, this rating scale considers five
different criteria associated with motor function. A score of 0 is defined
as normal, whereas a maximal score of 8 corresponds to a severely
affected animal displaying near-death recumbency.
At 16 d after removal of the minipumps, motor performances were also
assessed quantitatively in the elevated board test, using a video-based
motion tracking and analysis system, as described previously (Guyot et
al., 1997). Briefly, animals were trained for 5 d to run across an elevated
board. On the fifth day of training, all sham-operated animals were able
to cross the board without rearing or stopping, and a test run was
recorded for all groups of rats using a video recorder (VM-2900ES;
Hitachi, Tokyo, Japan), located laterally to the board. Images were
analyzed off-line. The instantaneous position of each animal’s geometric
center was determined in two dimensions (X–Y position) with a 3.9
mm/pixel spatial resolution and a 40 msec time resolution. Maximum
speed [peak tangential velocity (PTV)] and average tangential velocity
(ATV) were then calculated. Mean step size was also determined.
Histology. Animals were killed either at the end of the fifth day of the
neurotoxic treatment (experiment 1) or at 21 d, after behavioral testing
(experiment 2). All animals received an overdose of pentobarbital (120
mg/kg, i.p.; Sanofi, Libourne, France) and were perfused transcardially
with 100 ml of 0.1 M PBS, pH 7.4, followed by 250 ml of 4% parafor-
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maldehyde in 0.1 M phosphate buffer. Brains were removed, postfixed
overnight at 4°C in the same fixative, and cryoprotected in a 30% sucrose
solution. Coronal brain sections (40 m thick) were cut on a freezing
microtome and collected in an anatomical series; every 12th section was
stained with 0.15% gallocyanine (Gurr, Poole, UK). Remaining sections
were cryoprotected and stored at 20°C.
Immunocytochemical experiments were performed using a mouse
antivertebrate neuron-specific nuclear protein (NeuN; dilution 1:10,000;
Chemicon, Temecula, CA) or rabbit anti--galactosidase (dilution
1:2000; Chemicon). Brain sections were preincubated in PBS containing
5% normal goat serum (NGS) and 0.3% Triton X-100 for 30 min at room
temperature. Sections were incubated for 48 hr at room temperature in
PBS containing 3.5% NGS, 0.3% Triton X-100, 0.5% bovine serum
albumin, 0.05% sodium azide, and the primary antibody. Sections were
then processed by the avidin–biotin peroxidase method using Vec-
tastain avidin–biotin complex and VIP kits (Vector Laboratories,
Burlingame, CA).
Fluoro-Jade (Histo-Chem, Jefferson, AR), a fluorochrome that stains
degenerating neurons (Schmued et al., 1997), was used to document the
striatal lesion. Briefly, 40-m-thick sections were mounted, dried, and
immersed in 100% ethanol, followed by 70% ethanol and distilled water.
Sections were then treated with 0.06% potassium permanganate for 15
min. After rinsing, sections were immersed in Fluoro-Jade (0.001%
Fluoro-Jade in 0.1% acetic acid) for 30 min, rinsed, and rapidly air-dried
on a slide warmer.
Quantitative assessment of striatal lesions. The extent of the striatal
lesion produced by 3NP was determined in all animals of experiment 1
using a semiautomated image-analysis system. Six to seven equidistant
(200 m) gallocyanine-stained sections, selected to obtain a complete
rostrocaudal sampling of the striatum, were digitized using a computer-
assisted morphometry system consisting of an Olympus (Rungis, France)
AX70 photo-microscope and a Sony (Tokyo, Japan) HAD Power 3 CCD
color video camera connected to an Olympus Pentium II computer
equipped with the morphometry software Analysis Pro 3.0. The border
of the lesion was traced bilaterally at 1.5 magnification on each brain
section, and the respective lesion volumes were calculated according to
the method of Cavalieri.
In experiment 2, stereological neuronal counts were performed in
NeuN-immunostained sections from sham-operated animals (n  9),
AdRSV.CNTF-injected animals (n  8) and AdRSV.LacZ-injected ani-
mals (n  8), killed 16 d after removal of the osmotic minipumps. Under
these conditions, the striatal area of degeneration observed on day 5 of
the 3NP intoxication had disappeared, leaving a small scar detectable in
Figure 1. Microphotographs of one intrastriatal injection of
AdRSV.LacZ adenovirus in a 3NP-intoxicated rat (experiment 1,
group LacZ 10). A, Gallocyanine-stained section showing the bilateral
cell loss induced by the 3NP intoxication and its location in the lateral
part of the striatum. The injection needle track (arrow) is located
outside the area of cell loss. B, C, Section immunostained for -galac-
tosidase showing the distribution of immunoreactive cells along the
injection needle track (arrows, B). C (corresponding to the inset in B),
Note that not only the cell nuclei but also some cell processes express
-galactosidase. D, E, Distribution of neurons expressing -galactosi-
dase in the medial agranular cortex ( D) and in the substantia nigra
( E). The distribution of immunoreactive cell bodies corresponds to the
injection of AdRSV.LacZ adenovirus shown in B. Scale bars: B, D, E,
250 m; C, 60 m.
Table 1. Clinical rating scale used to quantify 3NP-induced motor
symptoms in rats
Score
Maximum score
(near-death rat)
Recumbency
All four legs active and four paws
facing the floor 0 —
Two hind legs unable to sustain walk
and body weight but forepaw able
to keep upright position balance 1 —
Animal lying on its side, falling when
put on its feet, showing rapid
breathing, uncoordinated move-
ments and chewing, almost com-
plete paralysis 2 2
Hind legs
Normal, active gait 0 —
Presence of intermittent dystonia in
one leg 1 —
Intermittent dystonia in two hind legs
or permanent dystonia in one hind
leg 2 —
Permanent dystonia in two hind legs 3 3
Gait
Normal gait 0 —
Presence of wobbling, uncoordinated,
jumpy gait 1 1
Balance
Ability to keep balance for 10 sec on
a 5  10 cm platform (15 cm
height) 0 —
Inability to keep balance 1 1
Grasping
Ability to grasp a cage grid with at
least one forepaw for 10 sec 0 —
Inability to grasp 1 1
Total 8
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the lateral part of the striatum, suggesting a spatial reorganization of the
surviving neurons and subsequent atrophy of the structure. For each
animal, the sections used for neuron counting covered the entire stria-
tum, pallidum, or rostral part of the medial agranular cortex in their
entire rostrocaudal length. On average, this corresponded to 11, 11, and
5 sections in the striatum, the pallidum, and the cortex, respectively, with
an interspace between adjacent sections of 440, 240, and 240 m, respec-
tively. Stereological countings were performed with C.A.S.T.-grid soft-
ware (Olympus, Albertslund, Denmark). The optical disector (West and
Gundersen, 1990) was used to obtain unbiased estimates of total numbers
of NeuN-immunoreactive neurons for each structure.
Data analyses. Data were analyzed using Statview (SAS Institute, Inc.,
Cary, NC; 1991). Statistical analysis was performed using paired or
unpaired t tests for lesion volume comparisons, a Mann–Whitney U
nonparametric test in the case of the motor impairment index, and a
factorial ANOVA followed by a post hoc Scheffe’s F test in all other cases.
Data are presented as mean  SEM.
RESULTS
All animals recovered uneventfully from administration of
adenovirus vectors and showed no behavioral side effects at
any time. The injection sites for the adenovirus vectors were
located in the medial third of the striatum, outside of the
dorsolateral striatal area of 3NP-induced neuronal loss (Fig.
1 A). In the injected striatum, both cells and fibers were immu-
noreactive for -galactosidase in a cylinder of a few hundred
micrometers in diameter around the needle track (Fig. 1B).
Immunostaining with -galactosidase also confirmed the ability
of the AdRSV.LacZ to transfer the LacZ gene not only to striatal
cells (Figs. 1B,C) but also to neurons located in various striatal
afferent regions such as the medial agranular cortex (Fig. 1D) and
the substantia nigra (Fig. 1E).
Temporal features of striatal neuroprotective effects
provided by AdRSV.CNTF (experiment 1)
Intoxication of rats by 3NP induced a striatal-selective lesion,
located in the lateral part of the structure (Fig. 1A). In agreement
with previous findings (Beal et al., 1993; Guyot et al., 1997; Ouary
et al., 2000), the lesion was characterized by a severe loss of
NeuN-immunopositive neurons (Fig. 2A,B) and intense Fluoro-
Jade staining within the lesion area (Fig. 2D), as opposed to the
complete absence of staining in the normal brain (Fig. 2C).
In rats injected in the left striatum with AdRSV.LacZ 10 d
before initiation of the 3NP intoxication (LacZ 10, n  6) (Fig.
2E), the mean volume of the striatal lesion was 16.1  1.6 and
17.6 2.6 mm3 in the left and right striatum, respectively, with no
statistical difference between the injected and noninjected sides.
In rats injected in the left striatum with AdRSV.CNTF 10 d before
initiation of the 3NP intoxication (Fig. 2E) (n  9, CNTF 10), a
64% reduction in lesion volume was observed compared with the
noninfected contralateral side (4.57  1.86 vs 12.71  1.46 mm3;
p  0.001). Waiting 30 or 90 d after infection before 3NP
intoxication (CNTF 30, n  6; CNTF 90, n  5) (Fig. 2E) did not
alter the neuroprotective potential of the CNTF treatment, de-
spite a significant time-dependent increase in lesion volume ob-
served in the noninfected striatum (factorial ANOVA; p  0.01),
a phenomenon related to the age dependency of the toxicity of
3NP (Brouillet et al., 1993). Three months after administration of
AdRSV.CNTF, PCR analysis demonstrated the presence of
NGFp-CNTF transgene mRNA in two different AdRSV.CNTF-
injected animals, in the infected (ipsilateral) striatum but not in
the noninfected (contralateral) striatum (Fig. 3).
Figure 2. Effects of unilateral striatal injections of adenovirus on the
volume of the striatal lesion induced by 3NP intoxication (experiment 1).
A–D, Photomicrographs of neurons identified by immunostaining for
NeuN (A, B) or by Fluoro-Jade staining (C, D) in the lateral striatum of
a normal (A–C) and a 3NP-intoxicated (B–D) animal. In B, note the
shrinkage and the loss observed in the neuronal population. This neuro-
nal loss is supported by the Fluoro-Jade staining of degenerative neurons
(D). E, Quantification of the volume of the 3NP-induced striatal lesion
confirms that the unilateral striatal injection of AdRSV.CNTF adenovi-
rus is associated with a reduction of the lesion in the injected striatum,
when the adenovirus has been injected 30 and 90 d as well as 10 d before
the beginning of the 3NP intoxication. Moreover, there is no statistical
difference between the lesion volumes obtained in the striatum of the
AdRSV.LacZ-injected group compared with the noninjected contralat-
eral striatum of the AdRSV.LacZ- and the AdRSV.CNTF-injected
groups when the adenovirus was injected 10 d days before the beginning
of the 3NP intoxication. p  0.01; unpaired t test. Scale bar: A, B, 100
m; C, D, 50 m.
Figure 3. Expression of transgenic mRNA for CNTF in the striatum
90 d after one injection of 5 10 8 AdRSV.LacZ adenovirus into the right
striatum of two rats. mRNA from the ipsilateral (lanes 3 and 5) and
contralateral (lanes 2 and 4 ) striatum was reverse transcribed and ampli-
fied by PCR. Transgenic CNTF was only found in the injected striatum,
at the predicted base pair (bp) size (arrow, lanes 2 and 4 ). Lane 1,
DNA/RNA molecular weight base pair standards.
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Spatial features of the neuroprotective effects
provided by AdRSV.CNTF (experiment 2)
In animals challenged with a 5 d 3NP intoxication starting 10 d
after bilateral administration of adenovirus vectors, the neuro-
protective potential of AdRSV.CNTF was studied using two dif-
ferent but complementary approaches: an in vivo qualitative (Fig.
4A) and quantitative (Fig. 4B–D) assessment of 3NP-induced
motor deficits, followed by postmortem stereological neuron
counts in the striatum, the pallidum, and the medial agranular
cortex of the same animals (Fig. 5).
As shown in Figure 4A, the first motor symptoms (lower limb
intermittent dystonia) were observed in both experimental groups
(animals treated with either AdRSV.LacZ or AdRSV.CNTF) on
the third day of treatment. The motor symptoms increased in
severity with time in both groups until the pumps were removed
at day 5. At this time point, as well as on day 4, CNTF-treated
animals (n  8) were significantly less affected by the toxic
treatment than the LacZ controls (n  8) ( p  0.05; Mann–
Whitney U test). All animals progressively recovered after pump
removal, but the CNTF-treated animals exhibited a lower motor
score than the LacZ controls at all time points studied ( p  0.05;
Mann–Whitney U test). No significant difference in weight loss,
recorded daily from day 1 to day 13, was observed between the
two groups.
After a 2 week resting period, the motor performances of
the three groups of animals (i.e., sham-operated animals,
AdRSV.CNTF-injected animals, or AdRSV.LacZ-injected and
3NP-intoxicated animals) were quantified in the elevated board
test (Fig. 4B–D). LacZ-injected animals (n  8) displayed a
significant decrease in PTV (an index of bradykinesia), a signif-
icant decrease in ATV (an index correlated with general locomo-
tor activity), and a significant decrease in step length (resulting
from severe bilateral leg dystonia) compared with the sham-
operated animals (n  9) ( p  0.01 vs sham animals). However,
animals belonging to the AdRSV.CNTF group exhibited PTV
values (Fig. 4B) and ATV values (Fig. 4C) that were not signifi-
cantly different from sham performances. The average step length
(Fig. 4D) was partially but significantly improved by CNTF treat-
ment (ANOVA; p  0.05; CNTF-treated vs either LacZ-treated
or sham-operated animals).
Stereological neuronal cell counts (Table 2; Fig. 5) performed
in the striatum and in regions containing afferent neurons to the
striatum [layers V and VI of the rostral portion of the medial
Figure 4. Experimental protocol (A) in experiment 2 and long-term
behavioral effects of the AdRSV.CNTF bilateral striatal injection on the
parameters quantifying motor abnormalities (A, motor index) and motor
performances (B, PTV; C, ATV; D, step length) in the three different
experimental groups. In A, note that from day 4 of the 3NP intoxication,
animals injected with the AdRSV.CNTF adenovirus ( gray bars) had a
better motor index score than the animals injected with the AdRSV.LacZ
adenovirus (black bars) (p 0.05; Mann–Whitney U test). The beneficial
effects of CNTF were different according to the parameters of motor
performances. The mean value obtained for PTV (index of bradykinesia,
B), was significantly higher in the CNTF group than in the LacZ group
and was not different from that obtained with the sham group. For the
mean values obtained for ATV (index of general activity, C), there was no
significant difference between either the CNTF and the sham groups or
the LacZ and the CNTF groups, but there was a significant difference
between the sham and the LacZ group. Finally, for the mean values
obtained for step length (D), there was no significant difference between
the LacZ and the CNTF groups, but both groups were significantly
different from the sham group (p  0.05; p  0.0001; ANOVA).
Figure 5. Protection of the neurons of the corticostriatopallidal pathway
induced by a bilateral injection of AdRSV.CNTF adenovirus into the
striatum (experiment 2). Stereological estimation of the number of neu-
rons immunoreactive for NeuN in layers V and VI of the right medial
agranular cortex (A, B), in the striatum (C), and in the pallidum (D)
shows that the protection of the striatal neurons is associated with a
statistically significant protection of the cortical and pallidal neurons
(p  0.0001; p  0.002; p  0.02; ANOVA).
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agranular cortex, or efferent striatal target cells (globus pallidus)]
(Reep et al., 1987; Berendse et al., 1992) were quite consistent
with the motor scores. In all considered areas of the LacZ-
infected animals, the number of NeuN-immunoreactive neurons
was significantly smaller than in sham animals, with decreases of
32, 75, and 39–36% observed in the striatum ( p 0.0001; factorial
ANOVA), the pallidum ( p  0.0001), and layers V and VI of the
cortex ( p  0.002), respectively. In the AdRSV.CNTF-injected
animals, the numbers of NeuN-immunoreactive neurons in cortical
layers V and VI were not significantly different from the numbers
observed in sham animals, but they were barely reduced in the
striatum ( p  0.02; factorial ANOVA) and significantly lower in
the pallidum ( p 0.002). The neuroprotection induced by CNTF
was therefore complete in both cortical layers (99–96% of sham
values), whereas only partial neuroprotection was observed in the
striatum (82%; p  0.02 vs sham) and the pallidum (70%; p 
0.01 vs sham; factorial ANOVA; Scheffe’s F test).
As shown in Figure 6, total numbers of neurons in the striatum
correlated linearly with total neuron numbers in the pallidum
(Fig. 6A) (r2  0.51; p  0.0001) and in the rostral portion of
medial agranular cortex layer V (Fig. 6B) (r2  0.57; p  0.0001)
and layer VI (Fig. 6C) (r2  0.67; p  0.0001). Despite some
intragroup heterogeneity, the LacZ-treated animals (n  8) as a
group were completely segregated from the two other experimen-
tal groups and the CNTF-treated animals (n  8) were in the
lower range of sham-operated animals (n  9).
To examine further the correlation between behavioral and
histological results, individual peak tangential velocities were
plotted against total striatal neuron numbers. As shown in Figure
7, there was a significant positive linear correlation between these
two parameters (r 2  0.547; p  0.003). Again, the group of rats
infected with the AdRSV.LacZ vector (n  8) was clearly sepa-
rated from the sham-operated control animals (n  9), whereas
AdRSV.CNTF-treated rats (n  8) were distributed in the lower
normal range. The same positive correlation was found between
striatal neuron numbers and ATV performance or step size (data
not shown).
DISCUSSION
The present study shows that one single-site striatal injection of
an adenovirus recombinant for CNTF protects not only striatal
neurons from degeneration but also cortical and pallidal neurons
in a rat model of progressive striatal degeneration. These neuro-
protective effects were associated with the persistence of trans-
gene expression in the injected striatum up to 3 months after
infection and correlated with a reduction of 3NP-induced behav-
ioral deficits. Together with previous data indicating the lack of
adverse effects using the same adenoviral vector at similar low
titers (Lisovoski et al., 1997), the current results show the thera-
peutic effect of adenovirus-mediated CNTF expression in the
brain.
Long-lasting transgene expression
One of the issues addressed in the present study was the demon-
stration of a long-lasting efficacy of cell infection with adenovirus-
mediated gene transfer. Because adenovirus vectors do not inte-
grate their genome into that of the transduced cells but rather
express it as an episome, it is generally believed that such gene
expression is only transient (Lee et al., 1993; Kozarsky et al.,
1994). Although this has been demonstrated clearly for cells that
divide after infection (Boviatsis et al., 1994), it is less well estab-
lished for nondividing cells such as neurons. To address the issue
of the duration of transgene expression in neurons, most authors
have relied on histochemical and/or immunocytochemical detec-
tion of the transgene product (Akli et al., 1993; Davidson et al.,
1993; Le Gal La Salle et al., 1993; Bennett et al., 1994; Ghodsi et
al., 1998; Bohn et al., 1999). Although the main objective was to
examine the neuroprotective effects of adenoviruses delivering
CNTF on maintaining the anatomical integrity of the structures
compromised in this animal model, we also measured behavioral
effects. The results clearly demonstrate neuroprotective effects in
terms of stereological counts and in some behavioral parameters.
The neuroprotection correlates with complete behavioral sparing
in one of the parameters tested (peak tangential velocity) and with
a partial sparing in step length, two parameters particularly sensi-
tive to 3NP intoxication (Ouary et al., 2000). The other kinetic
parameter, ATV, while being significantly altered by the 3NP
lesion, does not appear to be as restored by CNTF. The reason for
this difference is unclear and merits further investigation.
The use of stereological cell counts and behavioral studies
demonstrates the neuroprotective efficacy of the transgene prod-
uct up to 3 months after intrastriatal delivery of the viral vector.
Although this interval is still too short for a therapeutic use in
patients, it does indicate a protective effect of the transgene over
3 months. It also compares favorably with the available data
concerning other gene therapy delivery systems for a trophic
factor to the brain, such as adenoassociated virus vectors (Bosch
et al., 2000; Dhillon et al., 2000; Kirik et al., 2000), lentivirus
vectors (Kordower et al., 2000; Consiglio et al., 2001), and encap-
sulated engineered cells (Mittoux et al., 2000) that, up to now,
have shown relatively short survival times, requiring frequent
exchange of the device (Bachoud-Le´vi et al., 2000).
Retrograde infection of projecting neurons and
anterograde transport of the transgene product: two
properties of adenovirus vectors
In the present study, we demonstrate an effect of CNTF well
beyond the transfected striatal area. These results can be ex-
plained by a combination of intrinsic properties of adenoviral
vectors and CNTF on the one hand and the anatomical organi-
zation of the basal ganglia on the other. At the injection site (Fig.
8), mostly neurons but also glial cells are transfected (Peltekian et
al., 1997). Moreover, it is known that adenoviral vectors are taken
Table 2. Stereological NeuN-immunoreactive neuronal counts in the striatum, pallidum, and layers V and VI of the medial agranular cortex of
sham-operated (n  9), AdRSV.CNTF-treated (n  8), and AdRSV.LacZ-treated (n  8) rats
Groups Striatum Pallidum Cortical layer V Cortical layer VI
CNTF 3,203,827 123,765*,** 33,949  2803*,** 17,622  782* 10,019 443*
Sham 3,474,649  76,749 45,824 3844 18,869 967 11,077 559
LacZ 2,366,442  134,448** 12,668 1689** 11,587 829** 7,109 442**
*p  0.0001 versus LacZ; **p  0.002 versus sham (factorial ANOVA; Sheffe’s F test).
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up by axon terminals located in the infected area (in the present
case, the striatum) and are retrogradely transported to neuronal
cell bodies (Fig. 8) in the cerebral cortex, the substantia nigra pars
compacta, and other striatal afferent structures (Akli et al., 1993;
Bajocchi et al., 1993; Ridoux et al., 1994; Kuo et al., 1995). The
adenoviral vector then accumulates in the infected cell bodies and
it expresses the transgene, which is in turn anterogradely trans-
ported to axonal terminals and released (Lisovoski et al., 1997;
Terashima et al., 1997). In our case, the main area concerned by
the release of anterogradely transported transgene product is the
globus pallidus, which receives the bulk of its afferents from the
striatum. In addition, an intrastriatal release of transgenic CNTF
originating from the retrogradely transfected cortical areas and
substantia nigra may contribute to the neuroprotective effects
observed here.
Thus, local and distal expression of the transgene serves to
furnish CNTF to the striatum as well as to its afferent cortical
areas and to the efferent globus pallidus. The transgenic CNTF
released by the infected cells acts not only on these cells them-
selves (Hudgins and Levison, 1998) but also on the neuronal and
glial cells located within its diffusion zone (Baumgartner and
Shine, 1997), a process that further increases the sphere of the
neuroprotective effects of CNTF. CNTF induces astrocyte dif-
ferentiation and the upregulation of astrocyte CNTF synthesis,
thereby providing additional paracrine support to neurons (Clat-
terbuck et al., 1996; Lisovoski et al., 1997). Because astrocytes are
functionally as well as anatomically connected (Kim et al., 1994),
infection of local astrocytes by the AdRSV.CNTF vector may in
turn stimulate the subsequent synthesis and release of endoge-
nous CNTF by noninfected astrocytes located at a distance from
the vector injection.
Finally, the anatomical organization of the corticostriatopalli-
dal circuitry itself can influence the dispersion of viral particles,
because the transfection follows the connectivity. For example,
because corticostriatal input fibers are organized in a patchy way
within the striatum (Graybiel et al., 1991), the striatal volume
covered by the adenovirus injection can contain parts of one or
several of these patches, which will determine the number and the
volume of the cortical areas retrogradely transfected. However,
because of the convergence of corticostriatal inputs (Kincaid et
al., 1998), a large number of cortical neurons are potentially able
to be retrogradely transfected from a very restricted adenovirus
injection. These retrogradely transfected neurons will serve as
new sources of transgenic CNTF. In contrast, the high degree of
convergence and the spatial organization of the striatopallidal
Figure 6. Linear correlations between the number of striatal NeuN-
immunoreactive neurons and the number of neurons in the pallidum (A)
and in layers V (B) or VI (C) of the medial agranular frontal cortex.(A,
r 2  0.51, p  0.0001; B, r 2  0.57, p  0.0001; C, r 2  0.67, p  0.0001).
Figure 7. Linear correlation between the number of striatal NeuN-
immunoreactive neurons and the PTV of animals belonging to the
AdRSV.CNTF, AdRSV.LacZ, and sham groups (experiment 2). r 2 
0.547; p  0.003.
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connections (Yelnik et al., 1996) would confine the release of
transgenic CNTF only to a restricted part of the globus pallidus.
These anatomical organizations may account for the differences
in the neuroprotection observed in cortical layers and in the
pallidum.
Together, our data strongly support the notion that the initial
spatial restriction of the adenoviral infection around the site of
administration may not be a major problem in neuroprotective
therapeutic trials for HD.
Toward a clinical use of adenovirus-mediated
CNTF neuroprotection
The present study demonstrates that a single administration of
noncytotoxic amounts of adenoviral particles can be sufficient to
ensure widespread and long-lasting delivery of a therapeutic
transgene product. These results underscore the potential clinical
use of adenoviral vectors as a means to transfer genes into
patients with HD. Previous studies have indicated the potential
neuroprotective set of CNTF in the striatum using either im-
planted minipumps (Anderson et al., 1996) or encapsulated en-
gineered cells for delivery (Emerich et al., 1996; Mittoux et al.,
2000). The present study extends these observations by showing
that CNTF-expressing adenovirus vectors can neuroprotect neu-
rons located upstream and downstream from the striatum, and in
particular, the corticostriatopallidal pathway, a neuronal circuit
severely affected in HD. In addition to the potential interest of an
extrastriatal neuroprotection in HD, it is worth noting that this
may also benefit other pathologies that affect both striatal and
nigral neurons, such as multiple system atrophy or Steele–Ri-
chardson syndrome.
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